4157 Stock Overview
A pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
TaiGen Biopharmaceuticals Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$11.40 |
| 52 Week High | NT$17.25 |
| 52 Week Low | NT$10.60 |
| Beta | 0.92 |
| 1 Month Change | 0.89% |
| 3 Month Change | -17.69% |
| 1 Year Change | -23.75% |
| 3 Year Change | -24.50% |
| 5 Year Change | -48.76% |
| Change since IPO | -81.73% |
Recent News & Updates
Shareholder Returns
| 4157 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 5.6% | 1.1% | -1.4% |
| 1Y | -23.7% | 14.3% | 25.5% |
Return vs Industry: 4157 underperformed the TW Biotechs industry which returned 12.8% over the past year.
Return vs Market: 4157 underperformed the TW Market which returned 23.5% over the past year.
Price Volatility
| 4157 volatility | |
|---|---|
| 4157 Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4157 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4157's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Philip Huang | www.taigenbiotech.com.tw |
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibitor for the treatment of chronic hepatitis C; and Burixafor, a stem cell mobilizer which is in phase II clinical trial for stem cell transplantation and chemosenzitization.
TaiGen Biopharmaceuticals Holdings Limited Fundamentals Summary
| 4157 fundamental statistics | |
|---|---|
| Market cap | NT$8.18b |
| Earnings (TTM) | NT$171.74m |
| Revenue (TTM) | NT$148.75m |
47.6x
P/E Ratio55.0x
P/S RatioIs 4157 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4157 income statement (TTM) | |
|---|---|
| Revenue | NT$148.75m |
| Cost of Revenue | NT$13.80m |
| Gross Profit | NT$134.95m |
| Other Expenses | -NT$36.79m |
| Earnings | NT$171.74m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 90.72% |
| Net Profit Margin | 115.46% |
| Debt/Equity Ratio | 0% |
How did 4157 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/05 05:54 |
| End of Day Share Price | 2025/02/05 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TaiGen Biopharmaceuticals Holdings Limited is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Li-chun Chang | Jih Sun Securities Investment Consulting Co., Ltd. |
| Evana Chen | Masterlink Securities Corp. |
| Laurence Tam | Morgan Stanley |